Fractyl Health, Inc. (NASDAQ:GUTS) Director William Bradley Acquires 16,129 Shares of Stock

Fractyl Health, Inc. (NASDAQ:GUTS) Director William Bradley bought 16,129 shares of the business’s stock in a transaction that occurred on Thursday, March 13th. The stock was purchased at an average cost of $1.26 per share, for a total transaction of $20,322.54. Following the completion of the transaction, the director now directly owns 16,129 shares in the company, valued at approximately $20,322.54. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Fractyl Health Stock Down 0.8 %

Shares of NASDAQ GUTS opened at $1.27 on Tuesday. Fractyl Health, Inc. has a 12-month low of $1.16 and a 12-month high of $8.37. The company has a market cap of $62.13 million and a P/E ratio of -0.10. The company has a current ratio of 5.58, a quick ratio of 5.57 and a debt-to-equity ratio of 0.60. The stock has a fifty day moving average price of $1.64 and a 200 day moving average price of $2.16.

Fractyl Health (NASDAQ:GUTS) last announced its quarterly earnings results on Monday, March 3rd. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.08). Research analysts anticipate that Fractyl Health, Inc. will post -1.61 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, Morgan Stanley lowered their price target on Fractyl Health from $18.00 to $10.00 and set an “overweight” rating for the company in a report on Monday, February 3rd.

Institutional Trading of Fractyl Health

Several large investors have recently modified their holdings of GUTS. Massachusetts Financial Services Co. MA grew its stake in shares of Fractyl Health by 4.9% during the third quarter. Massachusetts Financial Services Co. MA now owns 1,045,672 shares of the company’s stock valued at $2,646,000 after acquiring an additional 49,289 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Fractyl Health by 56.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 80,664 shares of the company’s stock valued at $204,000 after acquiring an additional 29,262 shares in the last quarter. BNP Paribas Financial Markets grew its stake in shares of Fractyl Health by 54.1% during the third quarter. BNP Paribas Financial Markets now owns 21,072 shares of the company’s stock valued at $53,000 after acquiring an additional 7,397 shares in the last quarter. HighTower Advisors LLC acquired a new stake in shares of Fractyl Health during the third quarter valued at about $38,000. Finally, State Street Corp grew its stake in shares of Fractyl Health by 129.4% during the third quarter. State Street Corp now owns 113,415 shares of the company’s stock valued at $287,000 after acquiring an additional 63,968 shares in the last quarter.

About Fractyl Health

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.